BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Targeted Nanomedicines for the Resolution of Inflammation
DTSTART:20140304T143000
DTEND:20140304T153000
DTSTAMP:20260916T225604Z
UID:f0a28527bbe6360757e6c79cbdad141eba4c16c500ce046a6eb54743
CATEGORIES:Conferences - Seminars
DESCRIPTION:Nazila Kamaly\, Ph.D.\, Harvard Medical School\, MIT Koch Inst
 itute\, Brigham and Women’s Hospital\, Boston\, MA (USA)\nBio: - MSci\, 
 Medicinal Chemistry\, University College London\, U. of London (2002)\n- C
 hemical Data Editor\, Chapman & Hall/CRC Press\, UK Publishing House (2003
 )\n- PhD degree\, Imperial College London\, Department of Chemistry (2007)
 \n- Postdoc Chemist\, Medical Research Council\, Hammersmith Hospital (200
 7-09)\n- Research Associate\, Imperial College London\, Comprehensive Canc
 er Imaging Centre (2009-10)\n- Postdoctoral Research Fellow\, Brigham Wome
 n's Hospital\, Harvard Medical School and David H. Koch Institute for Inte
 grative Cancer Research at MIT\, Boston\, MA\, USA (2011-current)\n- Instr
 uctor\, Harvard Medical School & Brigham and Women's Hospital\, Boston\, M
 A\, USA (2013-current)\nAbstract:\nInflammation is an essential biological
  response that is required for tissue homeostasis after injury or infectio
 n. Chronic inflammation however is destructive\, can lead to tissue damage
 \, and is a hallmark of many diseases such as arthritis\, cardiovascular d
 isease\, and cancer. New potential therapeutic targets in addressing disea
 ses associated with unresolved inflammation and their underlying mechanism
 s are now being investigated and understood\, making therapeutics which da
 mpen inflammation and enhance resolution of considerable interest -  in p
 articular those which can achieve this in a controlled manner with minimal
  host collateral damage.\nNanomedicine encompasses a multidisciplinary app
 roach to drug delivery and has been driven in large part by discoveries in
  nanomaterials design and engineering\, which have enabled the accomplishm
 ent of the following milestones: 1) development of biodegradable nanocarri
 ers for the delivery of molecules of various sizes and solubilities\, in s
 ufficient loading amounts for therapeutic efficacy\, 2) selective accumula
 tion of therapeutics at disease sites and improved drug pharmacokinetic\, 
 biodistribution and degradation profiles due to careful optimization and e
 ngineering of nanoparticle biophysicochemical properties\, 3) the ability 
 to target any disease at the organ\, tissue\, cellular and sub-cellular le
 vels\, and 4) emerging clinical successes spanning a 40 year period.\nThis
  talk will present investigations into the development of targeted anti-in
 flammatory controlled-release polymeric nanomedicines for the treatment of
  inflammation driven diseases including atherosclerosis and colitis. The s
 ynthesis\, nanoengineering\, characterization and in vivo biological inves
 tigations of polymeric nanoparticles containing a payload of biologic drug
 s including a potent mediator biomimetic peptide and the anti-inflammatory
  cytokine IL-10 will be presented.
LOCATION:SV1717A http://map.epfl.ch/?room=sv1717a
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR